🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join us tomorrow at the ALS digital healthcare technology working group in Basel with a special focus on activity tracking #alsmndsymp #encals @TRICALS_cureALS Chris McDermott

BREAKING: EUpALS Industry Partner Ferrer regrets to inform the #ALS/#MND community that their Phase 3 ADORE trial with FAB122 (oral Edaravone) did not meet the primary and secondary endpoints. Read the press release at ALS.eu, section ALS Research News.

New paper about measuring body composition in people with #ALS #MND. Simple impedance provided a good estimate of fat-free mass. This could be valuable to better differentiate cause of weight loss and be an alternative for muscle strength testing in trials tandfonline.com/doi/full/10.10…

New #openacces paper with @jordivanunnik to evaluate the value of accelerometers to track disease in people living with #ALS #MND. We developed a novel metric to monitor and predict progression, and determine meaningful effects and wear time recommendations for clinical trials

Great to see this work out. A collaboration across 🇦🇺 🇨🇳 🇳🇱 we pave the way towards the notion that a standardised approach needs to be established for studies into hypermetabolism in #ALS #MND

Today, with Biogen, we announced results from the topline Phase 1/2 study of our investigational drug in people living with amyotrophic lateral sclerosis (#ALS). For more information about this program: ir.ionispharma.com/news-releases/…

New open-access paper Neurology Journal about factors that influence trial participation in #ALS #MND #AD #HD #PD clinical trials. These results will hopefully help to stimulate participation, better inform patients, and facilitate patient-centric approaches neurology.org/doi/10.1212/WN…

Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators bit.ly/3XfktoW

In the latest DEI blog, authors Weemering and Ruben van Eijk discuss barriers to inclusive clinical trial participation for neurodegenerative diseases and potentially modifiable factors to increase underrepresented patient populations. bit.ly/4d5msB1 #NeuroTwitter

Amyotrophic lateral sclerosis established as a multistep process across phenotypes | Multistep process has been established across #ALS; the number of steps to develop disease is different across clinical presentations Ruben van Eijk⁩ ⁦Steve Vucic⁩ pubmed.ncbi.nlm.nih.gov/39475283/

POTW 5: Patient Ranked Order of Function (PROOF) as a modified interpretation of the ALSFRS-R. An emerging alternative approach to optimize the detection of individualized function to predict survival and other outcomes in ALS. UMC Utrecht Ruben van Eijk doi.org/10.1212/WNL.00…

⁉️ ¿Te perdiste el VIII Encuentro Internacional de la #ELA en España? Un evento científico organizado por la #frAreces y la Fundación Luzón Recuerda que puedes verlo cuando quieras en nuestro canal 🖥️: · youtube.com/live/a-TSyp-Df… (ESP) · youtube.com/live/mLFVsSX13… (ENG)

Our study on the safety and tolerability of Trimetazidine in #ALS @BrainComms Trimetazidine reduced oxidative stress markers and energy expenditure, warranting a follow up study. Ruben van Eijk Derik Steyn Ammar Al-Chalabi academic.oup.com/braincomms/adv…

P A van Eijk et al. report that a trimetazidine trial for ALS showed it was safe and well-tolerated. It reduced oxidative stress markers and resting energy expenditure, suggesting potential for further study. Read at:buff.ly/HNd3No6 Ruben van Eijk Derik Steyn @AmmarAlChalab

Check out the findings of our review exploring the use of digital devices for monitoring physical behaviour in #MND jmir.org/2025/1/e68479 Chris McDermott Esther Hobson Alys Griffiths Derik Steyn Dr Liam Knox Ruben van Eijk Deirdre Murray Emma Hodson-Tole (She/Her) Professor Gladys Pearson Cory Holdom